NXTM NxStage Medical, Inc. featured news, full reports, and detailed charts
NxStage Medical, Inc. (NXTM) Wrap Up:
We are a medical device company that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. Our primary product, the NxStage System One TM , is a small, portable, easy-to-use hemodialysis system designed to provide physicians and patients improved flexibility in how hemodialysis therapy is prescribed and delivered. Given its design, the System One is particularly well-suited for home hemodialysis and more frequent, or “daily,” dialysis, which clinical literature suggests provides patients better clinical outcomes and improved quality of life. The System One is specifically cleared by the United States Food and Drug Administration, or FDA, for home hemodialysis as well as hospital and clinic-based dialysis. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f07%2f0000950135-08-001657.html#FIS_BUSINESS"Nxstage Medical, Inc. (NXTM:NASDAQ)
Snapshot of Nxstage Medical, Inc. (NXTM)
|
OPEN
$6.68
|
PREVIOUS CLOSE
$6.70
|
|
|
DAY HIGH
$6.68
|
DAY LOW
$6.26
|
|
|
52 WEEK HIGH
08/21/09 - $7.14
|
52 WEEK LOW
05/15/09 - $1.90
|
|
|
MARKET CAP
303.5M
|
AVERAGE VOLUME 3 mo
65.7K
|
|
|
DILUTED EPS TTM
$-0.96
|
SHARES OUTSTANDING
46.7M
|
|
|
NXTM Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
NXTM Top Compensated Officers
Executives, Board Directors
Key developments for Nxstage Medical, Inc. (NXTM)
Nxstage Medical Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported revenue of $38,033,000, loss from operations of $8,686,000, net loss before income taxes of $9,868,000, net loss of $10,047,000 or $0.22 diluted loss per share compared with revenue of $30,466,000, loss from operations of $12,259,000, net loss before income taxes of $14,827,000, net loss of $14,970,000 or $0.33 diluted loss per share over the same period last year. The Company's third quarter revenue includes approximately $2.5 million of third quarter sales within the In-Center market that management had previously expected to be deferred to the fourth quarter of 2009. For the third quarter of 2009, the Company had an Adjusted EBITDA loss of $2.4 million, adjusted for stock-based compensation, deferred revenue recognized and other non-recurring expenses, compared with an Adjusted EBITDA loss of $7.3 million in the third quarter of 2008. For the nine months, the company reported revenue of $108,166,000, loss from operations of $29,042,000, net loss before income taxes of $34,492,000, net loss of $34,790,000 or $0.75 diluted loss per share, net cash used in operating activities of $12,915,000 compared with revenue of $93,087,000, loss from operations of $38,841,000, net loss before income taxes of $41,200,000, net loss of $41,448,000 or $1.03 diluted loss per share, net cash used in operating activities of $46,953,000 over the same period last year. Adjusted EBITDA loss of $11.5 million against $23.2 million for the same period a year ago. The company provided earnings guidance for the fourth quarter of fiscal 2009. The company is forecasting revenue to be between $37 million to $39 million, a net loss in the range of $8.5 to $9.5 million or ($0.18) to ($0.21) per share, and an Adjusted EBITDA loss in the range of $1.5 to $2.5 million. Supported by its strong performance year to date in 2009, the Company now anticipates revenue for the 2009 fiscal year to be in a range of $145 to $147 million, compared with its prior guidance for revenue to be in a range of $135 to $145 million.
Nxstage Medical, Inc. expected to Report Fiscal Year 2009 Results on March 8, 2010. This event was calculated by Capital IQ (Created on November 5, 2009).
Nxstage Medical, Inc., Q3 2009 Earnings Call, Nov-05-2009
NXTM Competitors
| Company | Last | Change |
| AtriCure Inc | $5.86 USD | +0.075 |
| DexCom Inc | $7.27 USD | 0.00 |
| Dyax Corp | $3.91 USD | +0.26 |
| Inovio Biomedical Corp | $1.53 USD | +0.33 |
| SenoRx Inc | $4.53 USD | +0.1401 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | NXTM | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 2.1x |
|
| Price/Book | 3.2x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 1.7x |
|
|
NXTM |
||
NXTM transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||